Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment ...

SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve Replacement (TAVR). This alternative access procedure provides a critical, less ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Caranx Medical has submitted TAVIPILOT Soft, an AI-based guide software for use during Transcatheter Aortic Valve ...

Indraprastha Apollo Hospitals has launched a Heart Valve Clinic, offering advanced care for heart valve disorders. The clinic boasts cutting-edge technology and a multidisciplinary team for ...

Transcatheter aortic valve replacement (TAVR) is valve replacement without open-heart surgery. It is also called catheter-based or percutaneous (through the skin) aortic valve replacement. While ...

CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...

The first human TAVR was performed by Dr. Cribier in 2002. [33] There have been three generations of the Cribier-Edwards SAPIEN valve. The only valve that has FDA approval is the Edwards SAPIEN ...

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...

Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. New research findings comparing TAVR with clinical ...